Arcus Biosciences, Inc. (RCUS) financial statements (2021 and earlier)

Company profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1735871
Cash and cash equivalents1735871
Receivables2 0
Contract with customer, asset10 
Other undisclosed current assets560135188
Total current assets:736193259
Noncurrent Assets
Operating lease, right-of-use asset13 
Property, plant and equipment11911
Long-term investments and receivables6 1
Long-term investments6 1
Restricted cash and investments000
Other noncurrent assets610
Other undisclosed noncurrent assets  3
Total noncurrent assets:361016
TOTAL ASSETS:772203275
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities34149
Accounts payable1653
Accrued liabilities10106
Employee-related liabilities9  
Deferred revenue757
Other liabilities412
Other undisclosed current liabilities10 6
Total current liabilities:1222317
Noncurrent Liabilities
Long-term debt and lease obligation15  
Operating lease, liability15 
Liabilities, other than long-term debt133176
Deferred revenue12312
Deferred rent credit 44
Other liabilities1012
Other undisclosed noncurrent liabilities  17
Total noncurrent liabilities:1481723
Total liabilities:2703940
Stockholders' equity
Stockholders' equity attributable to parent502164235
Common stock000
Additional paid in capital830369358
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(328)(205)(123)
Total stockholders' equity:502164235
TOTAL LIABILITIES AND EQUITY:772203275

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:78158
Operating expenses(202)(104)(63)
Operating loss:(124)(89)(55)
Nonoperating income145
Loss from continuing operations before equity method investments, income taxes:(123)(85)(50)
Loss from equity method investments(1)  
Loss before gain (loss) on sale of properties:(123)(85)(50)
Other undisclosed net income1  
Net loss available to common stockholders, diluted:(123)(85)(50)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(123)(85)(50)
Other comprehensive income (loss)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(123)(85)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: